Research confirms benefits of side-actuated nasal spray

Published: 8-Feb-2010
Ingredients Drug Delivery Research & Development Pharmaceutical

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.

The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.

Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.

The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.




See more

You may also like

Manufacturing

Lilly partners with NVIDIA to build pharma’s most powerful AI supercomputer for faster drug discovery

Read more
Eli Lilly has joined forces with NVIDIA to create the world’s most powerful pharmaceutical supercomputer, designed to accelerate AI-driven medicine discovery and manufacturing — all while running entirely on renewable energy

Trending Articles

  1. Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
  2. Accelerating self-administration and homecare with large-volume prefillable glass syringe SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
  3. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research
  4. Takeda and Innovent Biologics partner to advance next-gen oncology medicines Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China

You may also like

Manufacturing

Lilly partners with NVIDIA to build pharma’s most powerful AI supercomputer for faster drug discovery

Eli Lilly has joined forces with NVIDIA to create the world’s most powerful pharmaceutical supercomputer, designed to accelerate AI-driven medicine discovery and manufacturing — all while running entirely on renewable energy
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Research & Development

Jabil and Kymanox collaboration to deliver end-to-end development, regulatory and manufacturing solutions

Jabil and Kymanox are partnering to combine their regulatory, technical, and manufacturing expertise to help life science companies streamline development and bring complex therapies to market faster
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Research & Development

Immunology CRO reports shift to autoimmunity projects

RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
Research & Development

Merck partners with Promega to advance 3D cell drug discovery technologies

Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Subscribe now